A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases
dc.contributor.author | Peterson, Andrew M. | en_US |
dc.contributor.author | Nau, David P. | en_US |
dc.contributor.author | Cramer, Joyce A. | en_US |
dc.contributor.author | Benner, Josh | en_US |
dc.contributor.author | Gwadry-Sridhar, Femida | en_US |
dc.contributor.author | Nichol, Michael | en_US |
dc.date.accessioned | 2010-06-01T22:34:57Z | |
dc.date.available | 2010-06-01T22:34:57Z | |
dc.date.issued | 2007-01 | en_US |
dc.identifier.citation | Peterson, Andrew M.; Nau, David P.; Cramer, Joyce A.; Benner, Josh; Gwadry-Sridhar, Femida; Nichol, Michael (2007). "A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases." Value in Health 10(1): 3-12. <http://hdl.handle.net/2027.42/75562> | en_US |
dc.identifier.issn | 1098-3015 | en_US |
dc.identifier.issn | 1524-4733 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75562 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17261111&dopt=citation | en_US |
dc.description.abstract | The increasing number of retrospective database studies related to medication compliance and persistence (C&P), and the inherent variability within each, has created a need for improvement in the quality and consistency of medication C&P research. This article stems from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) efforts to develop a checklist of items that should be either included, or at least considered, when a retrospective database analysis of medication compliance or persistence is undertaken. This consensus document outlines a systematic approach to designing or reviewing retrospective database studies of medication C&P. Included in this article are discussions on data sources, measures of C&P, results reporting, and even conflict of interests. If followed, this checklist should improve the consistency and quality of C&P analyses, which in turn will help providers and payers understand the impact of C&P on health outcomes. | en_US |
dc.format.extent | 84741 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | 2007, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) | en_US |
dc.subject.other | Compliance | en_US |
dc.subject.other | Guidelines | en_US |
dc.subject.other | Persistence | en_US |
dc.subject.other | Retrospective Databases | en_US |
dc.title | A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI, USA; | en_US |
dc.contributor.affiliationother | University of the Sciences in Philadelphia, Philadelphia, PA, USA; | en_US |
dc.contributor.affiliationother | Yale University, West Haven, CT, USA; | en_US |
dc.contributor.affiliationother | ValueMedics Research, LLC, Falls Church, VA, USA; | en_US |
dc.contributor.affiliationother | McMaster University, London, ON, Canada; | en_US |
dc.contributor.affiliationother | University of Southern California, Los Angeles, CA, USA | en_US |
dc.identifier.pmid | 17261111 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75562/1/j.1524-4733.2006.00139.x.pdf | |
dc.identifier.doi | 10.1111/j.1524-4733.2006.00139.x | en_US |
dc.identifier.source | Value in Health | en_US |
dc.identifier.citedreference | Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies—report of the ISPOR task force on retrospective databases. Value Health 2003; 6: 90 – 7. | en_US |
dc.identifier.citedreference | Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663 – 94. | en_US |
dc.identifier.citedreference | Pitkin RM, Branagan MA, Burmeister LF. Accuracy of data in abstracts of published research articles. JAMA 1999; 281: 1110 – 11. | en_US |
dc.identifier.citedreference | Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1998; 26: 814 – 23. | en_US |
dc.identifier.citedreference | Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999; 21: 1074 – 90. | en_US |
dc.identifier.citedreference | Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105 – 16. | en_US |
dc.identifier.citedreference | Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002; 27: 213 – 20. | en_US |
dc.identifier.citedreference | Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001; 10: 42 – 5. | en_US |
dc.identifier.citedreference | Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455 – 6. | en_US |
dc.identifier.citedreference | Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005; 62: 1468 – 75. | en_US |
dc.identifier.citedreference | Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147 – 52. | en_US |
dc.identifier.citedreference | Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004; 22 ( Suppl. 3 ): 13 – 23. | en_US |
dc.identifier.citedreference | Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231 – 51. | en_US |
dc.identifier.citedreference | Cramer JA, Sernyak M. Treatment options: switching atypical antipsychotic drugs or augmentation with divalproex, a naturalistic study. Clin Ther 2004; 26: 905 – 14. | en_US |
dc.identifier.citedreference | Cramer JA, Pugh MJ. The influence of insulin usage on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005; 28: 78 – 83. | en_US |
dc.identifier.citedreference | Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21 – 30. | en_US |
dc.identifier.citedreference | Levine M, Ensom MH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001; 21: 405 – 9. | en_US |
dc.identifier.citedreference | Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127 ( 8 Pt 2 ): 757 – 63. | en_US |
dc.identifier.citedreference | Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373 – 83. | en_US |
dc.identifier.citedreference | McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiology 2005; 161: 483 – 93. | en_US |
dc.identifier.citedreference | Skelton JR, Edwards SJ. The function of the discussion section in academic medical writing. BMJ 2000; 320: 1269 – 70. | en_US |
dc.identifier.citedreference | Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999; 318: 1224 – 5. | en_US |
dc.identifier.citedreference | Alpert JS, Furman S, Smaha L. Conflicts of interest: science, money, health. Arch Intern Med 2002; 162: 635 – 7. | en_US |
dc.identifier.citedreference | Hasegawa GR. Full disclosure. Am J Health-Sys Pharm 2002; 59: 1835. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.